FDA Approves LENZ Therapeutics’ VIZZ Eye Drop for Presbyopia

The FDA approved LENZ Therapeutics' VIZZ (aceclidine ophthalmic solution) 1.44% for the treatment of presbyopia in adults on August 1, 20251234.

VIZZ is the first and only FDA-approved aceclidine-based eye drop to improve near vision in adults with presbyopia, affecting approximately 128 million adults in the U.S.123.

VIZZ is a once-daily solution, clinically demonstrated to improve near vision for up to 10 hours following administration1234.

Its mechanism relies on a pupil-selective miotic effect, enhancing depth of focus via a 'pinhole effect' and minimizing ciliary muscle stimulation, thereby avoiding a myopic shift4.

Product samples are expected to be available in the U.S. as early as October 2025, with broad commercial availability by mid-Q4 2025123.

This approval represents a significant milestone, as previous biopharma attempts in the presbyopia eye drop market have struggled to achieve similar approval or product profile4.

Sources:

1. https://ir.lenz-tx.com/news-events/press-releases/detail/39/lenz-therapeutics-announces-us-fda-approval-of-vizz-for-the-treatment-of-presbyopia

2. https://mobile.visionmonday.com/technology/article/lenz-therapeutics-announces-fda-approval-of-vizz-for-treatment-of-presbyopia/

3. https://www.ophthalmologytimes.com/view/fda-approves-lenz-therapeutics-vizz-for-the-treatment-of-presbyopia

4. https://www.optometrytimes.com/view/fda-approved-lenz-therapeutics-vizz-for-the-treatment-of-presbyopia